0001493152-22-015543.txt : 20220601 0001493152-22-015543.hdr.sgml : 20220601 20220601085917 ACCESSION NUMBER: 0001493152-22-015543 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220530 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220601 DATE AS OF CHANGE: 20220601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 8i Acquisition 2 Corp. CENTRAL INDEX KEY: 0001847846 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40678 FILM NUMBER: 22986082 BUSINESS ADDRESS: STREET 1: C/O 6 EU TONG SEN STREET STREET 2: #08-13 THE CENTRAL CITY: SINGAPORE STATE: U0 ZIP: 059817 BUSINESS PHONE: 65 67880388 MAIL ADDRESS: STREET 1: C/O 6 EU TONG SEN STREET STREET 2: #08-13 THE CENTRAL CITY: SINGAPORE STATE: U0 ZIP: 059817 8-K 1 form8-k.htm
0001847846 false 0001847846 2022-05-30 2022-05-30 0001847846 LAX:UnitsConsistingOfOneOrdinaryShareNoParValueOneRedeemableWarrantToAcquireOnehalf12OfMember 2022-05-30 2022-05-30 0001847846 LAX:OrdinarySharesIncludedAsPartOfUnitsMember 2022-05-30 2022-05-30 0001847846 LAX:RedeemableWarrantsIncludedAsPartOfUnitsMember 2022-05-30 2022-05-30 0001847846 LAX:RightsIncludedAsPartOfUnitsMember 2022-05-30 2022-05-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 30, 2022

 

8i Acquisition 2 Corp.

(Exact Name of Registrant as Specified in its Charter)

 

British Virgin Islands   001-40462   n/a

(State or other jurisdiction

of  incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

c/o 6 Eu Tong Seng Street

#08-13 Singapore 059817

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: +65-6788 0388

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
         

Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of one Ordinary Share, and one Right to acquire one-tenth of an Ordinary Share

   LAXXU   NASDAQ Stock Market LLC
         
Ordinary Shares included as part of the Units   LAX   NASDAQ Stock Market LLC
         
Redeemable Warrants included as part of the Units   LAXXW   NASDAQ Stock Market LLC
         
Rights included as part of the Units   LAXXR   NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement

 

As previously announced, 8i Acquisition 2 Corp., a British Virgin Islands business company (“LAX”), entered into a Share Purchase Agreement (the “SPA”) dated April 11, 2022, with Euda Health Limited, a British Virgin Islands business company (“EUDA Health”), Watermark Developments Limited, a British Virgin Islands business company (the “Seller”) and Kwong Yeow Liew, acting as Representative of the Indemnified Parties (the “Indemnified Party Representative”). Pursuant to the terms of the SPA, a business combination between LAX and EUDA Health will be effected through the purchase by LAX of all of the issued and outstanding shares of EUDA Health from the Seller (the “Share Purchase”).

 

On May 30, 2022, parties amended the SPA (the “SPA Amendment”) to extend the time for LAX to complete its financial, operational and legal due diligence review of EUDA Health from May 31, 2022 to June 15, 2022.

 

Item 7.01 Regulation FD Disclosure.

 

On May 31, 2022, LAX and EUDA Health issued a joint press release announcing the execution of the SPA Amendment and related matters. A copy of the press release is furnished hereto as Exhibit 99.1.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Important Information for Investors and Stockholders

 

This document relates to a proposed transaction between LAX and EUDA Health. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. LAX intends to file a proxy statement with the SEC. A proxy statement will be sent to all LAX shareholders. LAX also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of LAX are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

 

Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by LAX through the website maintained by the SEC at www.sec.gov.

 

Forward Looking Statements

 

Certain statements included in this Current Report on Form 8-K are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K and on the current expectations of LAX’s and EUDA Health’s respective management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of LAX and EUDA Health. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions.

 

2
 

 

These forward-looking statements are subject to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, those factors described in the section entitled “Risk Factors” in the prospectus filed by LAX in connection with its initial public offering on November 22, 2021. Important factors, among others, that may affect actual results or outcomes include: the inability of the parties to successfully or timely consummate the Share Purchase, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect EUDA Health or the expected benefits of the Share Purchase, if not obtained; the failure to realize the anticipated benefits of the business combination; matters discovered by the parties as they complete their respective due diligence investigation of the other parties; the ability of LAX prior to the Share Purchase, and EUDA Health following the Share Purchase, to maintain the listing of LAX’s shares on NASDAQ; costs related to the business combination; the failure to satisfy the conditions to the consummation of the Share Purchase, including the approval of the SPA by the shareholders of LAX, the satisfaction of the minimum cash requirements of the SPA following any redemptions by LAX’s shareholders; the risk that the Share Purchase may not be completed by the stated deadline and the potential failure to obtain an extension of the stated deadline; and the outcome of any legal proceedings that may be instituted against LAX or EUDA Health related to the business combination. Important factors that could cause the combined company’s actual results or outcomes to differ materially from those discussed in the forward-looking statements include: EUDA Health’s limited operating history and history of net losses; EUDA Health’s ability to manage growth; EUDA Health’s ability to execute its business plan; EUDA Health’s estimates of the size of the markets for its products; the rate and degree of market acceptance of EUDA Health’s products; EUDA Health’s ability to identify and integrate acquisitions; potential litigation involving the Company or EUDA Health or the validity or enforceability of EUDA Health’s intellectual property; and general economic and market conditions impacting demand for EUDA Health’s products and services.

 

If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither LAX nor EUDA Health presently know, or that LAX and EUDA Health currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect LAX and EUDA Health’s current expectations, plans and forecasts of future events and views as of the date hereof. Nothing in this Current Report on Form 8-K and the attachments hereto should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this Current Report on Form 8-K and the attachments hereto, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and the risk factors of LAX and EUDA Health described above. LAX and EUDA Health anticipate that subsequent events and developments will cause their assessments to change. However, while LAX and EUDA Health may elect to update these forward-looking statements at some point in the future, they each specifically disclaim any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing LAX or EUDA Health’s assessments as of any date subsequent to the date of this Current Report. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Participants in the Solicitation

 

LAX and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from LAX’s shareholders with respect to the proposed transaction. Information regarding LAX’s directors and executive officers is available in its prospectus filed in connection with its initial public offering on November 22, 2021. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests will be contained in the proxy statement when it becomes available.

 

EUDA Health and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of LAX in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction will be included in the proxy statement for the proposed transaction when available. You may obtain free copies of these documents as described in the second paragraph under the above section entitled “Important Information for Investors and Stockholders.”

 

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit   Description
2.1   Amendment No. 1 to Share Purchase Agreement, dated as of May 30, 2022, by and among Euda Health Limited, Watermark Developments Limited, 8i Acquisition 2 Corp., and Kwong Yeow Liew.
99.1   Press Release issued by LAX and EUDA Health, dated May 31, 2022
104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

 

3
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 1, 2022

 

8i Acquisition 2 Corp.  
     
By: /s/ Meng Dong (James) Tan  
Name: Meng Dong (James) Tan  
Title: Chief Executive Officer  

 

4

 

 EX-2.1 2 ex2-1.htm

 

Exhibit 2.1

 

AMENDMENT NO. 1 TO THE

SHARE PURCHASE AGREEMENT

 

This Amendment No. 1 to the Share Purchase Agreement (this “Amendment”) is made as of May 30, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the “Company”), Watermark Developments Limited, a British Virgin Islands business company (“Seller”), and 8i Acquisition 2 Corp., a British Virgin Islands business company (“Purchaser”), and Kwong Yeow Liew, acting as Representative of the Indemnified Parties (the “Indemnified Party Representative”) and amends that certain Share Purchase Agreement dated April 11, 2022, by and among the Company, Seller, Purchaser, and the Indemnified Party Representative (the “Share Purchase Agreement”). The Company, Seller, Purchaser, and the Indemnified Party Representative are sometimes referred to separately in this Amendment as a “Party” and collectively as the “Parties.” Any capitalized term used in this Amendment and not otherwise defined herein shall have the meaning ascribed to such term in the Share Purchase Agreement.

 

RECITALS

 

WHEREAS, the Parties are parties to the Share Purchase Agreement;

 

WHEREAS, pursuant to Section 9.2(j) of the Share Purchase Agreement, a section that specifies a condition of Purchaser’s obligation to complete closing under the Share Purchase Agreement, Purchaser has until May 31, 2022 to (i) complete its financial, operational, and legal due diligence review of the Company (the “Due Diligence Review”) and (ii) provide written notice to Seller that Purchaser is not satisfied with the results of its Due Diligence Review;

 

WHEREAS, Purchaser will not have completed the Due Diligence Review by May 31, 2022;

 

WHEREAS, the Parties desire to extend the deadlines in Section 9.2(j) of the Share Purchase Agreement for Purchaser to have completed the Due Diligence Review and provide written notice to Seller as to Purchaser’s satisfaction with such review from “May 31, 2022” to “June 15, 2022”;

 

WHEREAS, Section 12.1 of the Share Purchase Agreement provides that the Share Purchase Agreement may be amended or modified if such amendment or modification is in writing and signed by each of Purchaser, the Indemnified Party Representative, Seller, and the Company; and

 

WHEREAS, the Parties to this Amendment constitute the parties necessary to amend the Share Purchase Agreement.

 

 

 

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the moneys being expended to complete the Due Diligence Review, the Parties agree as follows:

 

1. Amendment of the Share Purchase Agreement. Section 9.2(j) of the Share Purchase Agreement is hereby amended to change all references to “May 31, 2022” in such section to “June 15, 2022”, such amended section to read in its entirety as follows:

 

“(j) Satisfactory Completion of Due Diligence. The Purchaser shall have completed its financial, operational and legal due diligence review of the Company on or before June 15, 2022, and be satisfied with the results of such due diligence review. If the Purchaser has not notified the Seller in writing that it is not satisfied with the results of its due diligence review by close of business, New York time, on June 15, 2022, the closing condition of this Section 9.2(j) shall lapse without the necessity of any further action by the parties.”

 

2. No Other Amendment. Except as amended by this Amendment, the Share Purchase Agreement shall remain in full force and effect in accordance with its terms without any other amendment or modification.

 

3. Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of New York without regard to the conflict of law principles thereof (or any other jurisdiction) to the extent that such principles would direct a matter to another jurisdiction.

 

4. Counterparts. This Amendment (including any schedules and/or exhibits hereto or thereto) may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Remainder of Page Intentionally Left Blank]

 

2

 

 

In Witness Whereof, the parties hereto have executed this Amendment as of the date first set forth above.

 

COMPANY:  
     
EUDA HEALTH LIMITED  
     
By: /s/ Kelvin Chen Wei Wen  
Name: Kelvin Chen Wei Wen  
Title: CEO  
     
SELLER:  
     
Watermark Developments Limited  
     
By: /s/ Kelvin Chen Wei Wen  
Name: Kelvin Chen Wei Wen  
Title: Director  
     
PURCHASER:  
     
8I ACQUISITION 2 CORP.  
     
By: /s/ Guan Hong (William) Yap  
Name: Guan Hong (William) Yap  
Title: CFO  
     
INDEMNIFIED PARTY REPRESENTATIVE:  
     
  /s/ Kwong Yeow Liew  
Name: Kwong Yeow Liew  

 

3

 EX-99.1 3 ex99-1.htm

 

 Exhibit 99.1

 

8i Acquisition 2 Corp. and EUDA Health Limited Announce Extension of Due Diligence Review Period

 

Singapore, May 31, 2022 – 8i Acquisition 2 Corp. (the “Company” or “LAX”) (NASDAQ: LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited, a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare, today announced an amendment to the SPA (the “SPA Amendment”) to extend the time for LAX to complete its financial, operational and legal due diligence review of EUDA Health from May 31, 2022 to June 15, 2022.

 

As previously announced, LAX entered into a Share Purchase Agreement (the “SPA”) dated April 11, 2022, with Euda Health Limited (“EUDA Health”), Watermark Developments Limited, a British Virgin Islands business company (the “Seller”), and Kwong Yeow Liew, acting as Representative of the Indemnified Parties (the “Indemnified Party Representative”). Pursuant to the terms of the SPA, a business combination between LAX and EUDA Health will be effected through the purchase by LAX of all the issued and outstanding shares of EUDA Health from the Seller (the “Share Purchase”).

 

About 8i Acquisition 2 Corp.

 

8i Acquisition 2 Corp. is a British Virgin Islands company incorporated in January 2021 as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. LAX’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although LAX intends to focus on targets located in Asia.

 

About EUDA Health Limited

 

EUDA Health Limited, is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, and improving the patient experience by delivering better outcomes through personalized healthcare. The company’s proprietary unified AI platform quickly assesses a patient’s medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. EUDA Health’s holistic approach supports patients throughout all stages of care, including wellness & prevention, urgent care & emergencies, pre-existing conditions, and aftercare services. The company is expected to operate in five countries throughout Southeast Asia by the end of 2022.

 

Important Information for Investors and Stockholders

 

This announcement relates to a proposed transaction between LAX and EUDA Health and does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. LAX intends to file a proxy statement with the SEC. A proxy statement will be sent to all LAX shareholders. LAX also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of LAX are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

 

Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by LAX through the website maintained by the SEC at www.sec.gov.

 

Forward Looking Statements

 

Certain statements included in this Current Report on Form 8-K are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K and on the current expectations of LAX’s and EUDA Health’s respective management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of LAX and EUDA Health. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions.

 

 
 

 

These forward-looking statements are subject to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, those factors described in the section entitled “Risk Factors” in the prospectus filed by LAX in connection with its initial public offering on November 22, 2021. Important factors, among others, that may affect actual results or outcomes include: the inability of the parties to successfully or timely consummate the Share Purchase, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect EUDA Health or the expected benefits of the Share Purchase, if not obtained; the failure to realize the anticipated benefits of the business combination; matters discovered by the parties as they complete their respective due diligence investigation of the other parties; the ability of LAX prior to the Share Purchase, and EUDA Health following the Share Purchase, to maintain the listing of LAX’s shares on NASDAQ; costs related to the business combination; the failure to satisfy the conditions to the consummation of the Share Purchase, including the approval of the SPA by the shareholders of LAX, the satisfaction of the minimum cash requirements of the SPA following any redemptions by LAX’s shareholders; the risk that the Share Purchase may not be completed by the stated deadline and the potential failure to obtain an extension of the stated deadline; and the outcome of any legal proceedings that may be instituted against LAX or EUDA Health related to the business combination. Important factors that could cause the combined company’s actual results or outcomes to differ materially from those discussed in the forward-looking statements include: EUDA Health’s limited operating history and history of net losses; EUDA Health’s ability to manage growth; EUDA Health’s ability to execute its business plan; EUDA Health’s estimates of the size of the markets for its products; the rate and degree of market acceptance of EUDA Health’s products; EUDA Health’s ability to identify and integrate acquisitions; potential litigation involving the Company or EUDA Health or the validity or enforceability of EUDA Health’s intellectual property; and general economic and market conditions impacting demand for EUDA Health’s products and services.

 

If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither LAX nor EUDA Health presently know, or that LAX and EUDA Health currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect LAX and EUDA Health’s current expectations, plans and forecasts of future events and views as of the date hereof. Nothing in this Current Report on Form 8-K and the attachments hereto should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this Current Report on Form 8-K and the attachments hereto, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and the risk factors of LAX and EUDA Health described above. LAX and EUDA Health anticipate that subsequent events and developments will cause their assessments to change. However, while LAX and EUDA Health may elect to update these forward-looking statements at some point in the future, they each specifically disclaim any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing LAX or EUDA Health’s assessments as of any date subsequent to the date of this Current Report. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Participants in the Solicitation

 

LAX and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from LAX’s shareholders with respect to the proposed transaction. Information regarding LAX’s directors and executive officers is available in its prospectus filed in connection with its initial public offering on November 22, 2021. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests will be contained in the proxy statement when it becomes available.

 

 
 

 

EUDA Health and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of LAX in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction will be included in the proxy statement for the proposed transaction when available. You may obtain free copies of these documents as described in the second paragraph under the above section entitled “Important Information for Investors and Stockholders.”

 

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

 

For investor and media inquiries, please contact:

Gateway Group

IR: Cody Slach or Matthew Hausch

PR: Zach Kadletz or Catherine Adcock

Phone: (949) 574-3860

E-mail : LAX@gatewayir.com

 

 

 

 

 GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 5 lax-20220530.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 lax-20220530_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 lax-20220530_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of Ordinary Shares included as part of the Units Redeemable Warrants included as part of the Units Rights included as part of the Units Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 lax-20220530_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 30, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date May 30, 2022
Entity File Number 001-40462
Entity Registrant Name 8i Acquisition 2 Corp.
Entity Central Index Key 0001847846
Entity Incorporation, State or Country Code D8
Entity Address, Address Line One c/o 6 Eu Tong Seng Street
Entity Address, City or Town #08-13
Entity Address, Country SG
Entity Address, Postal Zip Code 059817
City Area Code 65
Local Phone Number 6788 0388
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of  
Title of 12(b) Security Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of
Trading Symbol LAXXU
Security Exchange Name NASDAQ
Ordinary Shares included as part of the Units  
Title of 12(b) Security Ordinary Shares included as part of the Units
Trading Symbol LAX
Security Exchange Name NASDAQ
Redeemable Warrants included as part of the Units  
Title of 12(b) Security Redeemable Warrants included as part of the Units
Trading Symbol LAXXW
Security Exchange Name NASDAQ
Rights included as part of the Units  
Title of 12(b) Security Rights included as part of the Units
Trading Symbol LAXXR
Security Exchange Name NASDAQ
XML 10 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001847846 2022-05-30 2022-05-30 0001847846 LAX:UnitsConsistingOfOneOrdinaryShareNoParValueOneRedeemableWarrantToAcquireOnehalf12OfMember 2022-05-30 2022-05-30 0001847846 LAX:OrdinarySharesIncludedAsPartOfUnitsMember 2022-05-30 2022-05-30 0001847846 LAX:RedeemableWarrantsIncludedAsPartOfUnitsMember 2022-05-30 2022-05-30 0001847846 LAX:RightsIncludedAsPartOfUnitsMember 2022-05-30 2022-05-30 iso4217:USD shares iso4217:USD shares 0001847846 false 8-K 2022-05-30 8i Acquisition 2 Corp. D8 001-40462 c/o 6 Eu Tong Seng Street #08-13 SG 059817 65 6788 0388 false true false false Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of LAXXU NASDAQ Ordinary Shares included as part of the Units LAX NASDAQ Redeemable Warrants included as part of the Units LAXXW NASDAQ Rights included as part of the Units LAXXR NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 5 22 1 false 4 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://8icorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex2-1.htm ex99-1.htm lax-20220530.xsd lax-20220530_def.xml lax-20220530_lab.xml lax-20220530_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "lax-20220530_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "lax-20220530_lab.xml" ] }, "presentationLink": { "local": [ "lax-20220530_pre.xml" ] }, "schema": { "local": [ "lax-20220530.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 67, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 4, "memberStandard": 0, "nsprefix": "LAX", "nsuri": "http://8icorp.com/20220530", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-05-30to2022-05-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://8icorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-05-30to2022-05-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "LAX_OrdinarySharesIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares included as part of the Units" } } }, "localname": "OrdinarySharesIncludedAsPartOfUnitsMember", "nsuri": "http://8icorp.com/20220530", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "LAX_RedeemableWarrantsIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants included as part of the Units" } } }, "localname": "RedeemableWarrantsIncludedAsPartOfUnitsMember", "nsuri": "http://8icorp.com/20220530", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "LAX_RightsIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights included as part of the Units" } } }, "localname": "RightsIncludedAsPartOfUnitsMember", "nsuri": "http://8icorp.com/20220530", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "LAX_UnitsConsistingOfOneOrdinaryShareNoParValueOneRedeemableWarrantToAcquireOnehalf12OfMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of" } } }, "localname": "UnitsConsistingOfOneOrdinaryShareNoParValueOneRedeemableWarrantToAcquireOnehalf12OfMember", "nsuri": "http://8icorp.com/20220530", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://8icorp.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 18 0001493152-22-015543-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-015543-xbrl.zip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